Notice of Results
31 March 2021
("Instem" or the "Company")
Notice of Results
Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, will announce results for the year ended 31 December 2020 on Monday 12 April 2021.
Analyst Presentation: 11:00, Monday 12 April
Management will be hosting a presentation via web conference on the day of the results at 11:00. Analysts wishing to join should register their interest by emailing firstname.lastname@example.org or by telephoning 020 7933 8780.
Investor Presentation: 16:00, Monday 12 April
Management will be providing a presentation and hosting an Investor Q&A session on the results and future prospects at 16:00hrs on the day, through the digital platform Investor Meet Company. Investors can sign up for free and add to attend the presentation via the following link https://www.investormeetcompany.com/instem-plc/register-investor
Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
For further information, please contact:
|Phil Reason, CEO||Via Walbrook|
|Nigel Goldsmith, CFO|
|N+1 Singer (Nominated Adviser & Broker)||+44 (0) 20 7496 3000|
|Wallbrook Financial PR||Tel: +44 (0) 20 7933 8780|
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.
Instem solutions are in use by over 500 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.
To learn more about Instem solutions and its mission, please visit instem.com.